GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Eurobio Scientific (OTCPK:DXNHF) » Definitions » Debt-to-Equity

Eurobio Scientific (Eurobio Scientific) Debt-to-Equity : 0.58 (As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is Eurobio Scientific Debt-to-Equity?

Eurobio Scientific's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $16.4 Mil. Eurobio Scientific's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $94.1 Mil. Eurobio Scientific's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $191.0 Mil. Eurobio Scientific's debt to equity for the quarter that ended in Dec. 2023 was 0.58.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Eurobio Scientific's Debt-to-Equity or its related term are showing as below:

DXNHF' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.1   Med: 0.54   Max: 0.8
Current: 0.58

During the past 13 years, the highest Debt-to-Equity Ratio of Eurobio Scientific was 0.80. The lowest was 0.10. And the median was 0.54.

DXNHF's Debt-to-Equity is ranked worse than
75.64% of 702 companies
in the Medical Devices & Instruments industry
Industry Median: 0.22 vs DXNHF: 0.58

Eurobio Scientific Debt-to-Equity Historical Data

The historical data trend for Eurobio Scientific's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eurobio Scientific Debt-to-Equity Chart

Eurobio Scientific Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.55 0.28 0.10 0.66 0.58

Eurobio Scientific Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.10 0.08 0.66 0.61 0.58

Competitive Comparison of Eurobio Scientific's Debt-to-Equity

For the Medical Devices subindustry, Eurobio Scientific's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eurobio Scientific's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Eurobio Scientific's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Eurobio Scientific's Debt-to-Equity falls into.



Eurobio Scientific Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Eurobio Scientific's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Eurobio Scientific's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Eurobio Scientific  (OTCPK:DXNHF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Eurobio Scientific Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Eurobio Scientific's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Eurobio Scientific (Eurobio Scientific) Business Description

Traded in Other Exchanges
Address
63-65 Boulevard Massena, Paris, FRA, 75013
Eurobio Scientific is one of the leading providers of specialty in vitro diagnostics and life-science solutions. The product portfolio includes Tetanos Quick Stick, BJI InoPlex, AlloMap, and TEDAC Consortium.

Eurobio Scientific (Eurobio Scientific) Headlines

No Headlines